Maybe they realise that Harry's best equipped to take us through to an oxy deal. I certainly don't have an issue with Harry being in charge for the next 12-24 months.
If there isn't anyone available better positioned to take us there, I certainly don't want a 'token' CEO taking the reigns.
In regards to elixia, it might be the last hurrah but their exposure in the USA has been outstanding compared to previous efforts.
So let's wait 3 more quarters to see if it can translate in $3-5m of extra revenue. If nothing eventuates in terms of sales this year, then I will agree it will unlikely do so.
Maybe they realise that Harry's best equipped to take us through...
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $20.06K | 10.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 32398999 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 46150696 | 25 |
View Market Depth
| Last trade - 13.15pm 13/09/2024 (20 minute delay) ? |
| AVE (ASX) Chart |